Roche Holding Ltd.'s phase 3 study of Alecensa for people with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer met its primary endpoint.
Under the study, Alecensa significantly improved progression-free survival of patients who were previously treated with chemotherapy and crizotinib compared to those on chemotherapy alone.
Alecensa is conditionally approved in Europe for patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer who have previously been treated with crizotinib alone. It is also approved as a monotherapy for patients who have progressed on or are intolerant to crizotinib in the U.S. and nine other countries.
ALK-positive NSCLC is a form of lung cancer commonly diagnosed in younger people and in women. About 75,000 people are diagnosed with the disease globally each year.